Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001104659-25-110358
Filing Date
2025-11-12
Accepted
2025-11-12 16:10:50
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 10462
2 EXHIBIT 1 tm2530940d1_ex-1.htm EX-99.1 7659
  Complete submission text file 0001104659-25-110358.txt   19923
Mailing Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116
Business Address 322 NORTH 2200 WEST SALT LAKE CITY UT 84116 801-584-3600
MYRIAD GENETICS INC (Subject) CIK: 0000899923 (see all company filings)

EIN.: 870494517 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-48577 | Film No.: 251472798
SIC: 2835 In Vitro & In Vivo Diagnostic Substances
(CF Office: 03 Life Sciences)

Mailing Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022
Business Address C/O MILLENNIUM MANAGEMENT LLC 399 PARK AVENUE NEW YORK NY 10022 (212) 841-4100
INTEGRATED CORE STRATEGIES (US) LLC (Filed by) CIK: 0001319244 (see all company filings)

EIN.: 980330397 | Fiscal Year End: 1231
Type: SCHEDULE 13G/A